Quizzes

Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?

In the real-world analysis comparing dasatinib and nilotinib as second-line therapies in CML-CP, what was the observed MMR rate at 12 months among patients treated with nilotinib?

Did the addition of pertuzumab retreatment to trastuzumab and physician’s choice chemotherapy improve survival among patients with HER2-positive, locally advanced or metastatic breast cancer?

What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?

Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?

According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?

Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?

Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?

Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?

Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!